Vertex Pharmaceuticals Reports Primary Phase 3 Results for Trikafta in Cystic Fibrosis

Vertex Pharmaceuticals today announced primary Phase 3 trial results for Trikafta (elexacaftor/tezacaftor/ivacaftor) in patients with cystic fibrosis who have at least one F508del mutation. The trial met its primary endpoint, demonstrating a significant improvement in ppFEV1 of 14.3 percentage points compared to placebo. Sweat chloride levels were also significantly reduced. These results led to FDA approval of Trikafta.